-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CF3gjS7fOcUsiMar4bVy7jaqMSR/m0m8+pPbZYRf1Iy1I3A2aHtb5mwdaBRxsdJJ OIh4wkj7c9PJ4OL/55OT5A== 0001454982-09-000064.txt : 20090306 0001454982-09-000064.hdr.sgml : 20090306 20090306201859 ACCESSION NUMBER: 0001454982-09-000064 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090304 FILED AS OF DATE: 20090306 DATE AS OF CHANGE: 20090306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Gergen Mark J CENTRAL INDEX KEY: 0001373110 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19700 FILM NUMBER: 09664649 BUSINESS ADDRESS: BUSINESS PHONE: 858-552-2200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMYLIN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000881464 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330266089 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6195522200 MAIL ADDRESS: STREET 1: 9360 TOWNE CENTRE DR STREET 2: SUITE 110 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 edgardoc.xml PRIMARY DOCUMENT X0303 4 2009-03-04 0 0000881464 AMYLIN PHARMACEUTICALS INC AMLN 0001373110 Gergen Mark J 9360 TOWNE CENTRE DR SAN DIEGO CA 92121 0 1 0 0 Sr VP Corporate Development Common Stock 2009-03-04 4 A 0 2550 0 A 3455 I by ESOP Common Stock 5667 D Incentive Stock Option (right to buy) 9.02 2009-03-04 4 A 0 3439 0 A 2016-03-04 Common Stock 3439 3439 D Non-Qualified Stock Option (right to buy) 9.02 2009-03-04 4 A 0 30000 0 A 2016-03-04 Common Stock 30000 30000 D Non-Qualified Stock Option (right to buy) 9.02 2009-03-04 4 A 0 51561 0 A 2016-03-04 Common Stock 51561 81561 D These shares fully vest four years from the date of the reporting person's participation in the ESOP in four equal annual installments and are generally distributed upon termination of employment. 25% of shares vest one year from date of grant and the remainder vest monthly over the next three years becoming fully vested four years from date of grant. These performance-based options fully vest only if Amylin's drug candidate exenatide once weekly is approved for commercial use by year-end 2010. If this business objective is not attained by December 31, 2010, the options will be forfeited. Direct holdings include 1,161 shares acquired on February 27, 2009 under the company's employee stock purchase plan. By: /s/Lloyd A. Rowland, Attorney-in-Fact For: Mark J. Gergen 2009-03-06 -----END PRIVACY-ENHANCED MESSAGE-----